Cordis Corp., a Johnson & Johnson (NYSE:JNJ) subsidiary, said it inked an exclusive deal to distribute TriReme Medical’s Chocolate PTA balloon catheter.
The Chocolate PTA device is designed to treat peripheral artery disease
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
By Chris Walker
Cordis Corp., a Johnson & Johnson (NYSE:JNJ) subsidiary, said it inked an exclusive deal to distribute TriReme Medical’s Chocolate PTA balloon catheter.
The Chocolate PTA device is designed to treat peripheral artery disease
Interventional Spine said it secured expanded 510(k) clearance from the FDA for its Opticage spine implant
The Irvine, Calif.-based company makes implants used in spine surgeries, with a focus on osteoporosis-afflicted bones. expandable interbody fusion device.
Smith & Nephew (FTSE:SN, NYSE:SNN) said it’s launching its Polarstem cementless hip stem in the United States for total hip replacement procedures.
Cayenne Medical is $1 million away from reaching its $6 million fundraising goal, according to a regulatory filing.
Scottsdale, Ariz.-based Cayenne Medical makes medical devices used in knee and shoulder reconstruction surgeries.
Nine unnamed investors ponied up a collective $5 million in the equity and options sale, according to the filing.
Biolase (NSDQ:BIOL) said it closed a $5 million private placement with Oracle Investment Management.
The surgical laser maker sold off a little more than 1.9 million shares for $2.57 each, with the deal closing on Feb. 10. The money is expected to go toward paying down its $4.6 million credit facility with Comerica Bank, according to chairman & CEO Federico Pignatelli .
Smiths Medical president Srini Seshadri is expected to step down, and Zimmer (NYSE:ZMH) executive Jeff McCaulley will step into the top office.
There was no reason given for Seshadri’s departure. He joined the company in 2006 and helped navigate some tough times when it was under-performing, Smiths said.
Pulse Therapeutics is nearing its $1.5 million goal in an active fundraising effort that has so far brought in just over $1 million, according to a SEC filing.
St. Louis-based Pulse Therapeutics is developing stroke treatment technologies based on tiny, biologically safe iron particles that could deliver drug therapy.
Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.
Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company’s 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.